Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
09 May 2016 | North America | Market Research
US and Western European Atrial Fibrillation Market, Forecast to 2025
Demand-Supply Gaps Create Space for New Technologies and Products, Cardiac Mapping Systems and Robotic Magnetic Systems to Witness Strong Growth
The evolution of new products and technology has impacted the type of procedures conducted, and clinicians must ensure that they keep pace with these advancements. These factors will play a major role in the adoption of new products, thereby boosting procedure volumes. Ablation continues to strengthen its value proposition in various healthcare s...
$4,950.00 -
17 May 2016 | North America | Market Research
Medical Imaging Services Market in France, Forecast to 2020
New Regional Health Initiatives Revitalize Growth Prospects, Motivate Phased Adoption of Managed Equipment Services (MES) and Multi-Vendor Services (MVS)
France is far behind Netherlands, which has the highest penetration rate of medical imaging contracts under non-conventional business models such as managed equipment services (MES) and multi-vendor services (MVS), and behind the United Kingdom, which has the largest number of such contracts. The French Ministry of Health’s substantial cost-cutti...
$3,000.00 -
23 Jun 2016 | North America | Market Research
Growth Opportunities in the US Point-of-care Testing Market
Digital Health Meets Point of Care—Emergence of Mobile Molecular Diagnostics
The US point-of-care testing (POCT) study provides an extensive analysis for 13 segments: hematology, urinalysis, infectious disease, cardiac, HbA1c, glucose, fecal occult blood test/fecal immunochemical test (FOBT/FIT), coagulation PT/INR, coagulation APTT/ACT, cholesterol, pregnancy, drugs of abuse, and blood gas and electrolytes. Key trends and ...
$4,950.00 -
13 Sep 2016 | North America | Market Research
US Next-generation Sequencing Services Market
$1,000 Genome Pricing and Throughput to Drive More and Larger Sequencing Projects
The next-generation sequencing (NGS) services market includes all sequencing services conducted with next-generation or third-generation platforms that use newer technology than traditional capillary electrophoresis (CE) sequencing. Services include project scoping, NGS sample preparation tasks (i.e., library prep and target enrichment), and NGS-ba...
$4,950.00 -
08 Nov 2016 | North America | Market Research
The US Molecular Diagnostics Market, Forecast to 2021
Polymerase Chain Reaction (PCR) Holds Close to 53% Share but Strong Clinical Research will Push NGS to Revolutionize this Space in the Next 5 to 10 Ye
The US molecular diagnostics market is growing at 12.5% CAGR and is set to reach close to $6.5 billion by 2021. PCR, next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in this space with PCR holding more than 75% of the market. Roche, Cepheid, Qiagen, Abbott, and Thermo Fisher do...
$4,950.00 -
11 Nov 2016 | North America | Market Research
Global Orphan Drug Market
High Pricing and Undefined Reimbursement Policies will Limit the Sales of Orphan Drugs
The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...
$6,000.00
